Specialty Pharmacy

Decrease attributed to less toxic therapies and risk reduction measures.

The FDA today approved Novartis' secukinumab (Cosentyx), an interleukin-17A antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Hospira has received 510(k) regulatory clearance from the FDA for its Plum 360 medication infusion system with Hospira MedNet safety software.

Process may reduce bowel obstructions and surgeries.

Although teixobactin is ineffective against most gram-negative organisms, its potent activity against gram-positive organisms, including vancomycin-resistant enterococci, may help delay the postantibiotic era by decades.

A new FDA-approved drug will provide a new treatment option for adult and pediatric patients undergoing continuous renal replacement therapy.

Raulo Frear, PharmD, general manager of OmedaRx, discusses methods to enhance management of drug utilization programs.

Study warns there is no testing to support a net clinical benefit.

Study finds lack of adherence to sun protection recommendations.

A new study on the effects of cancer patients' financial burdens suggests that pharmacists can play a role in easing or preventing some of their stress.

Discovery may provide hope for treatment of most common form of brain cancer.

In May 2014, the Centers for Disease Control published a guideline document to help pharmacists and other health care professionals avoid common pitfalls of vaccine cold-temperature storage that may affect the efficacy and safety of vaccines.

United States devoting less resources to pharmaceutical industry.

Walgreens official discusses programs and techniques for improving patient adherence.

Chemoradiotherapy regimen before surgery found to be effective in patients with localized rectal cancer.

Pharmacy Times, the pharmacy industry's number 1 journal and the most read publication among pharmacists and pharmacy professionals, and its sister publication, Specialty Pharmacy Times, continue to expand their Strategic Alliance Partnership programs by adding new member organizations.

Thirty-eight of 40 hepatitis C patients treated with 3-drug combination cured in a recent trial.

Sunitinib found to provide unprecedented antitumor activity in treatment of thymic carcinoma.

The National Governors Association is exploring and supporting pharmacists' expanding role in providing direct patient care outside of dispensing medications.

Price Chopper Supermarkets is pleased to announce the launch of its new specialty pharmacy program, which expands pharmacy services in an effort to provide more convenient and personalized solutions for patients living with chronic and complex health conditions. This program is part of a partnership with Aureus Health Services, a specialty pharmacy and health management company.

CVS and Prime Therapeutics agreements follow Express Scripts in hepatitis C formulary updates.

The British National Health Service announced yesterday that it will drop 16 cancer drugs from the list of treatments funded through its Cancer Drugs Fund.

Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses developments in contracting that specialty pharmacies need to be aware of.

Attacking protein could potentially treat a number of conditions, including the Ebola virus, brain cancer, and hepatitis.

Improper vaccine storage is surprisingly common and may be one cause of the rising incidence of vaccine-preventable diseases across the United States.

Data published in The Lancet Infectious Diseases on Jan. 8 shows that some contraceptives for women may increase the risk of contracting HIV. This information comes from researchers from the University of California Berkeley, who analyzed 12 studies.

Study finds many patients not receiving radiation treatment.

American Cancer Society reports significant progress in death rates.

Supreme Court to decide legality of offering subsidies to low- and moderate-income people who purchase coverage through federally run health insurance marketplaces.

Most patients treated with high-dose immunosuppressive therapy and who had their own hematopoietic stem cells transplanted experienced sustained remission after 3 years.